Join
Live feed
·
PRReleasevia Quantisnow
BioMarin Pharmaceutical Inc. logo

BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency

ByQuantisnow·Wall Street's wire, on your screen.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BMRN (BioMarin Pharmaceutical Inc.) and more on Quantisnow.